Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: GlobeNewswire
– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Regularly Transfused, PYRUKYND® Demonstrated a Statistically Significant and Clinically Meaningful Reduction in Transfusion Burden – – Following FDA Approval in February, PYRUKYND® Is the First and Only Disease-Modifying Treatment for Adults with PK Deficiency – CAMBRIDGE, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today announced that data from the core period of the pivotal Phase 3 ACTIVATE-T study of PYRUKYND® (mitapivat) in adults with pyruvate kinase (PK) deficiency who receive regular transfusions were published on August 18, 2022, in The Lancet Haematology. Data from this study were previously presented at the 2021 European Hematology Association (EHA) Annual Congress. PYRUKYND® is a first-in-class, oral PK activator and the first and only approved disease-modifying treatment fo
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024GlobeNewswire
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Agios Publishes 2024 Environmental, Social and Governance (ESG) Report [Yahoo! Finance]Yahoo! Finance
- Agios Publishes 2024 Environmental, Social and Governance (ESG) ReportGlobeNewswire
- We Think Agios Pharmaceuticals (NASDAQ:AGIO) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 11/2/23 - Beat
AGIO
Sec Filings
- 4/10/24 - Form 4
- 3/11/24 - Form 4
- 3/7/24 - Form 4
- AGIO's page on the SEC website